Navigation Links
Progen to Present Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
Date:11/2/2007

BRISBANE, Australia, Nov. 2 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today announced that Dr. James Garner, Progen's Vice President of Clinical and Medical Affairs will present a poster entitled "The Interactive Effect of Prognostic Factors and PI-88 Use on the Delay of HCC Recurrence Following Curative Partial Hepatic Resection" at the 58th Annual Meeting of the American Association for the Study of Liver Diseases in Boston, USA(1) on Saturday, 3 November 2007.

The poster presentation will be made available on Progen's website http://www.progen-pharma.com from approximately 9am (Brisbane time) Saturday 3 November 2007.

(1) Each year, the American Association for the Study of Liver Diseases brings together over 6,000 hepatologists and hepatology health professionals from around the world for its annual meeting to meet and exchange the latest liver disease research, and discuss treatment outcomes.

About PI-88: PI-88 is one of a new class of multi-targeted cytostatic cancer therapeutics. It is a novel anti-cancer compound with a first-in-class mechanism as a heparan sulfate mimetic. Its anti-tumor activity is based on inhibition of two biological processes -- angiogenesis (the growth of new blood vessels) and metastasis (the spread of cancer to other sites) -- critical to the growth and progression of cancer. In a phase 2 trial in post- resection liver cancer, 160mg of PI-88 demonstrated a 25% improvement in the primary endpoint of disease-free rate at 48 weeks and 78% improvement in secondary endpoint of disease-free survival. These results, combined with positive feedback from the FDA, provide Progen with confidence in the potential of PI-88 for this indication and we are therefore aggressively pursuing its development towards registration and commercialization.

About Progen: Progen Pharmaceuticals Limited is an Australia-based globally focused biotechnology company committed to the discovery, development and commercialization of small molecule therapeutics primarily for the treatment of cancer.


'/>"/>
SOURCE Progen Pharmaceuticals Limited
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. The secrets for a healthy progeny: Mother’s diet during pregnancy
2. Lizard Mothers Dress Their Progeny to Ensure Success in Later Life
3. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
4. Researchers Present Ways To Reduce The Risk Of Dementia
5. Researchers Present Data Regarding The Efficiency Of Herbs
6. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
7. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
8. Drug Reactions First Present Themselves In The Mouth
9. Reminiscing Into The Past Makes You Dissatisfied With The Present
10. Living In The Past Indicates Dissatisfaction With Present
11. Movies Represent Coma In A Wrong Way
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... February 20, 2017 , ... ReportingMD, a Population Health Software Company, is pleased to ... company. The new location will triple the size of the previous location while bringing ... of Sunapee, NH. , “We are excited to expand our footprint to better ...
(Date:2/20/2017)... Tampa, FL (PRWEB) , ... February 20, 2017 ... ... $20,000 gift from Constellation Brands to purchase a new ultrasound-enhanced thrombolysis machine, a ... ultrasonic waves. The gift was facilitated by the Pepin Family Foundation. , “We ...
(Date:2/19/2017)... ... February 19, 2017 , ... Orbita, ... will join forces with Healthwise ® at HIMSS 2017 to ... leader in evidence-based health education, technology and services, will demonstrate a voice-powered knowedge ...
(Date:2/18/2017)... ... ... Park Cities Pet Sitter President, Joette White, has been featured on Episode ... The episode, which was posted this week, features a 30-minute interview of White by ... Pet Sitter’s being awarded the 2017 National Association of Professional Pet Sitter’s Business of ...
(Date:2/17/2017)... ... February 17, 2017 , ... The Alliance Healthcare Foundation (AHF) ... further positively impact the health and wellness of our community in San Diego ... duty to seriously consider releasing our assets beyond our 5% targeted distribution each ...
Breaking Medicine News(10 mins):
(Date:2/19/2017)... 19, 2017  nThrive™, an independent Patient-to-Payment? solutions ... thought leadership at the 2017 HIMSS Conference. The ... award from KLAS. nThrive will host ... how market trends shape the holistic, integrated revenue ... comprehensive Patient Access solution. The panel will reveal ...
(Date:2/18/2017)... DUBLIN , Feb. 17, 2017 Research and ... Business Report" report to their offering. ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , Latin America ... for the period 2015 through 2022. Also, a six-year historic analysis is ...
(Date:2/17/2017)... -- According to a new market research report "Particle ... (Cleanroom Monitoring, Contamination Monitoring of Liquids), and End User (Healthcare Industry, ... market is expected to reach USD 330.6 Million by 2021 from ... 2016 to 2021. Continue Reading ... ...
Breaking Medicine Technology: